News Focus
News Focus
icon url

Investor2014

01/06/18 11:33 AM

#136560 RE: TheBigTicket #136558

Hope Missling wasn't allegedly entering the Pfizer building looking for some in-licensing potential.
icon url

anders2211

01/06/18 11:33 AM

#136561 RE: TheBigTicket #136558

thats really incredible news all BP are pulling out of CNS....
icon url

XenaLives

01/06/18 11:40 AM

#136562 RE: TheBigTicket #136558

WOW! Maybe they have decided to avoid the iceberg.

icon url

XenaLives

01/06/18 12:37 PM

#136566 RE: TheBigTicket #136558

I fount this to be really interesting - from your link:


In the fall of 2016 Pfizer recruited Harvard professor Ole Isacson to head up neurosciences work, celebrating the company’s commitment to making breakthrough efforts on Alzheimer’s and Parkinson’s. Isacson, though, quietly left just 9 months later, in May of last year.

icon url

ExtremelyBullishZig

01/06/18 2:22 PM

#136572 RE: TheBigTicket #136558

Ouch! Possible partners dropping. Missling will have to start saying soon that he needs to raise money to afford 3 trials.
icon url

plexrec

01/06/18 2:56 PM

#136575 RE: TheBigTicket #136558

Big Ticket...good find---perhaps Pfizer saw what cards TGD is holding--and saw they were all Aces !!! Ha--Big Pharma has had a complicated relationship with neurosciences---Pfizer folded to cut their losses !
icon url

plexrec

01/06/18 3:02 PM

#136576 RE: TheBigTicket #136558

More from Pfizer (thanks to Big Ticket)--In the fall of 2016 Pfizer recruited Harvard professor Ole Isacson to head up neurosciences work, celebrating the company’s commitment to making breakthrough efforts on Alzheimer’s and Parkinson’s. Isacson, though, quietly left just 9 months later, in May of last year.----Perhaps Pfizer should closely scrutinize Anavex's pipeline--to get "up to speed" in the neuroscience area